# Treatment of Hematological Malignancy With Novel CAR-T Cells.

> **NCT04191941** · EARLY_PHASE1 · UNKNOWN · sponsor: **Timmune Biotech Inc.** · enrollment: 9 (estimated)

## Conditions studied

- B-cell Non Hodgkin Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Novel CAR-T

## Key facts

- **NCT ID:** NCT04191941
- **Lead sponsor:** Timmune Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2019-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04191941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04191941, "Treatment of Hematological Malignancy With Novel CAR-T Cells.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04191941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*